Anteris Technologies

We are excited to share new data at Sydney Valves next week! On Friday, March 21 Dr. Rishi Puri will present in the Late-Breaking Clinical Trial session with new data from DurAVR? THV clinical experience. Not attending? Sign up here for clinical data updates ?? https://bit.ly/3Dw1O0G #TAVI #TAVR #aorticstenosis #SydneyValves Rohan Bhagwandeen DurAVR? INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.?

Why might DurAVR? THV be an important addition to TAVR? At the CRT conference this week, Dr. Eberhard Grube presented about the native-shaped biomimetic design of the DurAVR? TAVR valve and its impact on restoring physiologic laminar flow and reducing LV mass. For more information, visit our website ?? https://bit.ly/4bMCShU #TAVR #TAVI #physiologicflow #laminarflow #cardiachypertrophy #biomimetic DurAVR? INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.?

At the CRT conference this week, Dr. Isaac George M.D., FACC, FACS presented about advances in leaflet technologies used in replacement heart valves and featured the ADAPT? tissue technology from Anteris. ADAPT?-treated tissue has been clinically proven to be calcium-free through 10 years of follow-up* and is also designed to be anti-fibrotic.** The patented native-shaped molding of the tissue used for the biomimetic DurAVR? Transcatheter Heart Valve is designed to reduce leaflet stressors by minimizing leaflet pinwheeling and fluttering.*** Learn more about the science that went into developing the ADAPT? tissue technology and biomimetic DurAVR? TAVR valve in this paper recently published in Frontiers: https://lnkd.in/gDRcYBdZ #TAVI #TAVR #aorticstenosis #biomimetic DurAVR? INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use. References: *Neethling W, Rea A, Forster G, Bhirangi K. Performance of the ADAPT-Treated CardioCel? Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes, Front Pediatr, 2020;8:198? **C?té N, Pibarot P, and Clavel MA, Incidence, risk factors, clinical impact, and management of bioprosthesis structural valve degeneration. Curr Opin Cardiol. 2017;32: 123-129.? **Konakci KZ, Bohle B, Blumer R, Hoetzenecker W, Roth G, Moser B, Boltz-Nitulescu G, Gorlitzer M, Klepetko W, Wolner E, and Ankersmit HJ. Alpha-Gal on bioprostheses: xenograft immune response in cardiac surgery. Eur J Clin Invest. 2005;35(1):17-23.? **Badylak SF, and Gilbert TW. Immune response to biologic scaffold materials. Semin Immunol. 2008;20(2): 109-16.? ***Anteris Data on File

This #InternationalWomensDay, we celebrate the women who are shaping the future of structural heart treatments, from our talented engineers to our dedicated medical professionals across the globe. At Anteris, we are committed to accelerating action. Together, with our EmpowHer employee resource group, we are creating inclusive work cultures where women’s careers thrive and their achievements are celebrated. ?? #IWD #AccelerateAction #InspireInclusion #WomenInSTEM

In this fireside chat at the TD Cowen Healthcare Conference, Anteris CEO Wayne Paterson discusses the history of the company and how we sought to address unmet needs in aortic stenosis patients. Anteris created a first-in-class biomimetic TAVR valve by asking different questions and solving a different problem. ?? https://lnkd.in/g6YpWKtC ? “We should be looking at curative outcomes where we can, not just treating symptoms…We’re seeing that?shift in other therapeutic?areas such as oncology, where the focus is on trying to address the root cause.” - Wayne Paterson ? Listen here?to learn about how we designed a TAVR valve built to mimic the performance of a pre-disease aortic valve and restore healthy heart function ?? https://lnkd.in/g6YpWKtC ? #TDCowen TD Securities #TAVR #TAVI #aorticstenosis #MedTech Joshua Jennings ? DurAVR? INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

Check out this recent podcast from DeviceTalks! Anteris CEO Wayne Paterson describes how the company leveraged the revolutionary ADAPT? anti-calcification tissue technology to enter the TAVR space by creating the first biomimetic TAVR valve, meaning it is designed to mimic the performance of a healthy aortic valve. ?? https://lnkd.in/eeTt-5-U #TAVI #TAVR #aorticstenosis #MedTech DurAVR? INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

Today is Heart Valve Disease Awareness Day, and Anteris stands committed to advancing cardiovascular care and raising awareness about this critical condition. Over half of those with clinically significant heart valve disease are undiagnosed.* In this video, our Chief Medical Officer Christopher Meduri explains aortic stenosis, a type of heart valve disease, and common symptoms. #HeartDisease #ValveDiseaseDay #aorticstenosis #HeartMonth *Reference: d’Arcy JL, Coffey S, Loudon MA, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. Eur Heart J. 2016;37(47):3515- 3522. doi:10.1093/eurheartj/ehw229

Last week we enjoyed engaging with physicians at the THT Conference, which focuses on therapies for heart failure. We featured a poster on the impact of the DurAVR? biomimetic TAVR valve design on flow patterns and LV mass regression post-implantation. We look forward to continuing to move the conversation forward in TAVR by partnering with heart failure physicians and studying the impact of aortic stenosis and valve replacement on the entire cardiovascular system. View the poster: https://lnkd.in/gxeCqFGn #MovingtheConversationForward #TAVR #TAVI #aorticstenosis #cardiachypertrophy #heartfailure Jo?o Cavalcante DurAVR? INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE. EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

Great podcast! Our CEO's perspective on the future of #TAVR is out and reinforces our commitment to moving the conversation forward in TAVR. #MovingtheConversationForward #aorticstenosis #TAVI #MedTech DurAVR? INVESTIGATIONAL USE ONLY. NOT AVAILABLE FOR COMMERCIAL SALE.?EU: Exclusively for clinical investigations. US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.

Today our employees wore red in recognition of Wear Red Day, a day dedicated to raising awareness about heart disease, particularly among women. Heart disease is the leading cause of death among women and men in the US, yet many women go undiagnosed.* Women with aortic stenosis are less likely (37% vs 63%) to be treated than men in the US, despite equal prevalence.** Raising awareness and promoting prevention is crucial for improving treatment rates in women. Learn more about signs of heart disease here: https://lnkd.in/ds9aHuB? ? ? #WearRedDay #HeartHealth #HealthyHeart #GoRedForWomen References: *National Center for Health Statistics. Multiple Cause of Death 2018–2022 on CDC WONDER Database. Accessed May 3, 2024.?https://lnkd.in/gt9BhG59 **Brennan MJ, Leon MB, Sheridan P, et al. Racial Differences in the Use of Aortic Valve Replacement for Treatment of Symptomatic Severe Aortic Valve Stenosis in the Transcatheter Aortic Valve Replacement Era. J Am Heart Assoc. 2020;9(16):e015879. **Alkhouli M, Holmes DR, Carroll JD, et al. Racial Disparities in the Utilization and Outcomes of TAVR: TVT Registry Report. JACC Cardiovasc Interv. 2019;12(10):936-948.